Sign In
Buy KNSA
$47.85
+0.93 (+1.98%)
At Close: Jun 03, 2026
Wall Street Analysts Think Kiniksa Pharmaceuticals, Ltd. (KNSA) Could Surge 100%: Read This Before Placing a Bet
12:15pm, Wednesday, 03'rd Nov 2021
The average of price targets set by Wall Street analysts indicates a potential upside of 100.2% in Kiniksa Pharmaceuticals, Ltd. (KNSA). While the effectiveness of this highly sought-after metric is q
Kiniksa Pharmaceuticals (KNSA) CEO, Sanj Patel on Q3 2021 Results - Earnings Call Transcript
11:50am, Monday, 01'st Nov 2021
Kiniksa Pharmaceuticals (KNSA) CEO, Sanj Patel on Q3 2021 Results - Earnings Call Transcript
Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q3 Loss, Tops Revenue Estimates
10:43am, Monday, 01'st Nov 2021
Kiniksa Pharmaceuticals, Ltd. (KNSA) delivered earnings and revenue surprises of 30.16% and 21.93%, respectively, for the quarter ended September 2021.
Kiniksa Pharmaceuticals to Report Third Quarter 2021 Financial Results on November 1, 2021
04:01pm, Friday, 29'th Oct 2021
HAMILTON, Bermuda, Oct. 29, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Monday, November 1, 2021, at 8
Kiniksa Pharmaceuticals to Present at 2021 Cantor Fitzgerald Virtual Global Healthcare Conference
04:01pm, Tuesday, 21'st Sep 2021
HAMILTON, Bermuda, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Confere
Kiniksa: Unexciting, Slow Growth Stock
01:22pm, Friday, 13'th Aug 2021
Kiniksa has one approved product and multiple late-stage programs. The cash balance is strong and a small revenue stream has started.
Kiniksa Pharmaceuticals' (KNSA) CEO Sanj Patel on Q2 2021 Results - Earnings Call Transcript
11:34am, Tuesday, 03'rd Aug 2021
Kiniksa Pharmaceuticals' (KNSA) CEO Sanj Patel on Q2 2021 Results - Earnings Call Transcript
Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q2 Loss, Tops Revenue Estimates
10:42am, Tuesday, 03'rd Aug 2021
Kiniksa Pharmaceuticals, Ltd. (KNSA) delivered earnings and revenue surprises of 11.59% and 200.94%, respectively, for the quarter ended June 2021.
Kiniksa Pharmaceuticals to Present at 2021 Wedbush PacGrow Healthcare Conference
04:01pm, Monday, 02'nd Aug 2021
HAMILTON, Bermuda, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 2021 Wedbush PacGrow Healthcare Conference on Tuesday, A
Kiniksa Pharmaceuticals to Report Second Quarter 2021 Financial Results on August 3, 2021
04:01pm, Tuesday, 20'th Jul 2021
HAMILTON, Bermuda, July 20, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, August 3, 2021 at 8:3
Kiniksa Announces Issuance of U.S. Patent for Treatment of Recurrent Pericarditis
04:01pm, Tuesday, 08'th Jun 2021
HAMILTON, Bermuda, June 08, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a portfolio of assets designed to modulate immunolog
Kiniksa Outlines Next Steps for the Development of Mavrilimumab
07:30am, Tuesday, 08'th Jun 2021
- Defined regulatory pathway for Phase 3 clinical development of mavrilimumab in multiple indications -
Kiniksa Pharmaceuticals to Present at Goldman Sachs 42nd Annual Global Healthcare Conference
04:01pm, Tuesday, 01'st Jun 2021
HAMILTON, Bermuda, June 01, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the Goldman Sachs 42nd Annual Global Healthcare Conference o
20 Short Ideas With Super-Weak Momentum
10:39am, Monday, 31'st May 2021
Often, weak stocks going into a market correction or bear move will decline faster than the main indexes. I have listed 20 stocks/ETFs out of a 4000+ sort universe experiencing a rush of selling since
Kiniksa: A Look At Mavrilimumab
08:01am, Monday, 03'rd May 2021
Kiniksa is testing Mavrilimumab in giant cell arteritis and COVID-19. It has produced strong data in either indication.
